Bone marrow microvessel density and vascular endothelial growth factor expression in patients with aplastic anemia.
- Author:
Li ZHANG
1
;
Hui-jun WANG
;
Hong-qiang LI
;
Dong-lin YANG
;
Zhang-song YAN
;
Yu-hong WU
;
Kang ZHOU
;
Yu-lin CHU
;
Hui-shu CHEN
;
Feng-kui ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Anemia, Aplastic; metabolism; pathology; Bone Marrow; blood supply; metabolism; Child; Female; Humans; Male; Microvessels; pathology; Middle Aged; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A; metabolism
- From: Chinese Journal of Hematology 2007;28(8):528-531
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the bone marrow microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression and their clinical significance in patients with aplastic anemia (AA).
METHODSBone marrow biopsies in 51 newly diagnosed patients with AA were evaluated the MVD and VEGF expression by immunostaining with anti-factor VIII related antigen and VEGF monoclonal antibodies at regular time points after immunosuppressive therapy (IT).
RESULTSThe mean bone marrow MVD in AA group was 5.5 +/- 3.5, being significantly lower than that in normal control group (8.7 +/- 3.4, P < 0.05). MVDs of SAA and NSAA patients were 7.4 +/- 2.9 and 4.3 +/- 3.4, respectively, being significantly different (P < 0.01). The VEGF expression in AA group was significantly lower than that in control group [(6.7 +/- 8.4)% vs (14.7 +/- 6.1)%, P < 0.01], but there was no difference between SAA and NSAA. Bone marrow MVD and VEGF were significantly increased after IT in 22 responded AA patients.
CONCLUSIONBone marrow MVD and VEGF expression are low in AA patients which may be one of pathophysiologic mechanisms of bone marrow failure in AA. Proangiogenic and ameliorating microcirculation agents together with IT might accelerate the recovery of hematopoiesis in AA patients.
